Emyria |
Market Cap (5-Nov) $30,654,068 (923rd) |
Close (30-Jun) $0.125 |
Volume (30-Jun) 0 |
Shortsold (29-Oct) 161,639 (0.02%) (557th) |
|
52w High $0.078 |
52w Low $0.036 |
P/E - |
EPS -0.01 |
Strong Recruitment for EMD-RX5 Phase 3 Trial
EMD released this announcement to the ASX on 23 March 2023, 8:16. The announcement is marked as price sensitive, and is 4 page(s) in length and 1.19MB in size.
You can view all announcements from EMD and see how they appear on a price chart on the announcements page.
At the date of this announcement, EMD was 0.086% short sold according to ASIC data. It was ranked the 470th most shorted stock on the ASX. It remains ranked 557th as of the latest reported data (29 October 2026).
| Other Recent Announcements from EMD | |
|---|---|
| Trading Halt | 29 June 2023, 9:33 |
| Emyria Receives Ethics Approval for MDMA-assisted Therapy | 8 June 2023, 9:10 |
| Section 708A(5)(e) Notice | 10 May 2023, 18:37 |
| Strong Recruitment for EMD-RX5 Phase 3 Trial | 23 March 2023, 8:16 |
| Emyria Grows MDMA Asset for Neuro & Mental Health Therapy | 20 March 2023, 8:10 |
| Broker Briefing Presentation | 16 March 2023, 8:13 |
| Broker Briefing Biotech & Nutrition Investor Webinar | 15 March 2023, 10:35 |
If you were already registered, log in here.